Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Lilly’s Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer’s
Donanemab Has Dosing, Cost Advantages Over Eisai/Biogen Drug
Jul 03 2024
•
By
Mandy Jackson
The path to anti-amyloid treatment remains long but more centers are prepared to treat • Source: Shutterstock
More from New Products
More from Scrip